NCT02322840

Brief Summary

PILOT: The study is a pilot trial to evaluate the safety and performance of the Twelve TMVR System in high risk mitral regurgitation patients. EFS: The study is an Early Feasibility Study to evaluate the safety and performance of the Medtronic Intrepid™ Transcatheter Mitral Valve Replacement System with Transfemoral Transseptal access in Patients with moderate-Severe or severe, Symptomatic Mitral Regurgitation

Trial Health

82
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
128

participants targeted

Target at P50-P75 for not_applicable

Timeline
31mo left

Started Apr 2015

Longer than P75 for not_applicable

Geographic Reach
7 countries

32 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress81%
Apr 2015Dec 2028

First Submitted

Initial submission to the registry

October 31, 2014

Completed
2 months until next milestone

First Posted

Study publicly available on registry

December 23, 2014

Completed
3 months until next milestone

Study Start

First participant enrolled

April 1, 2015

Completed
7.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2022

Completed
3.2 years until next milestone

Results Posted

Study results publicly available

November 24, 2025

Completed
3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2028

Expected
Last Updated

January 14, 2026

Status Verified

December 1, 2025

Enrollment Period

7.4 years

First QC Date

October 31, 2014

Results QC Date

August 26, 2025

Last Update Submit

December 19, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Percent of Subjects With Adverse Events

    PILOT: Site Reported Serious Adverse Events Implant or Delivery Related Through 30-Days EFS: Implant, Delivery or device related serious adverse events through 30 days post procedure

    30 days

Secondary Outcomes (9)

  • Number of Subjects With Procedural Success

    Procedure

  • Change in Mitral Regurgitation (MR) From Baseline Through 30 Days

    30 days

  • Change in Mitral Regurgitation (MR) From Baseline Through 30 Days

    Through 30 Days

  • Change in New York Heart Association (NYHA) From Baseline Through 30 Days

    Through 30 days

  • Change in New York Heart Association (NYHA) From Baseline Through 30 Days

    Through 30 Days

  • +4 more secondary outcomes

Study Arms (1)

Transcatheter Mitral Valve Replacement (TMVR) Implant

EXPERIMENTAL

Twelve TMVR Implant

Device: Twelve TMVR ImplantDevice: Medtronic Intrepid™ Transcatheter Transfemoral Mitral Valve Replacement System

Interventions

Implantation of the Twelve TMVR System - Apical

Also known as: Medtronic Intrepid™ Transcatheter Mitral Valve Replacement System
Transcatheter Mitral Valve Replacement (TMVR) Implant

Implantation of the Medtronic Intrepid™ Transcatheter Mitral Valve- Transfemoral

Also known as: Medtronic Intrepid™ Transcatheter Mitral Valve Replacement System
Transcatheter Mitral Valve Replacement (TMVR) Implant

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Severe mitral regurgitation (PILOT)
  • moderate-severe or severe mitral regurgitation (EFS)
  • Symptomatic mitral regurgitation (NYHA Class II-IV)
  • Deemed to be at high risk for conventional mitral valve surgery by the local heart team (including, at minimum, a cardiac surgeon, interventional cardiologist, and an echocardiologist) (PILOT and EFS)
  • Subjects anatomically suitable for the Intrepid TMVR delivery system, including transfemoral and transseptal access (EFS only)
  • Native mitral valve geometry and size compatible with the Intrepid™ TMVR (PILOT)

You may not qualify if:

  • Left ventricular ejection fraction (LVEF) \< 20 (PILOT) or \<30% (EFS)
  • Evidence of intracardiac mass, thrombus, or vegetation
  • Prior valve surgery or need for other valve surgery
  • Prior stroke within 30 days (PILOT) or 90 days (EFS)
  • Gastrointestinal bleeding within 6 months (PILOT)
  • Prior myocardial infarction 90 days (EFS)
  • Need for coronary revascularization
  • History of, or active, endocarditis if antibiotics are required (EFS)
  • Renal insufficiency; Serum Creatinine \> 2.5 mg/dL (PILOT) or Creatinine Clearance \<30 cc/min (EFS)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (32)

Abrazo Arizona Heart Hospital - EFS

Phoenix, Arizona, 85016, United States

Location

Cedars-Sinai Medical Center - PILOT

Los Angeles, California, 90048, United States

Location

Piedmont Atlanta Hospital - PILOT

Atlanta, Georgia, 30309, United States

Location

Northwestern Memorial Hospital - PILOT

Chicago, Illinois, 60208, United States

Location

University of Michigan Health System - University Hospital - PILOT

Ann Arbor, Michigan, 48109, United States

Location

Corewell Health - EFS

Grand Rapids, Michigan, 49503, United States

Location

Abbott Northwestern Hospital - EFS

Minneapolis, Minnesota, 55407, United States

Location

Abbott Northwestern Hospital - PILOT

Minneapolis, Minnesota, 55407, United States

Location

Barnes Jewish Hospital - PILOT

St Louis, Missouri, 63110, United States

Location

NYU Langone Medical Center - PILOT

New York, New York, 10016, United States

Location

The Mount Sinai Hospital (New York NY) - EFS

New York, New York, 10029, United States

Location

The Mount Sinai Hospital (New York NY) - PILOT

New York, New York, 10029, United States

Location

New York-Presbyterian Hospital Columbia University Medical Center - EFS

New York, New York, 10032, United States

Location

New York-Presbyterian Hospital Columbia University Medical Center - PILOT

New York, New York, 10032, United States

Location

Oregon Health & Science University Hospital - EFS

Portland, Oregon, 97239, United States

Location

UPMC Pinnacle Harrisburg Campus - EFS

Wormleysburg, Pennsylvania, 17043, United States

Location

Baylor Jack and Jane Hamilton Heart and Vascular Hospital - PILOT

Dallas, Texas, 75246, United States

Location

Houston Methodist Hospital - PILOT

Houston, Texas, 77030, United States

Location

University of Virginia Medical Center - EFS

Charlottesville, Virginia, 22908, United States

Location

Aurora Saint Luke's Medical Center - EFS

Milwaukee, Wisconsin, 53215, United States

Location

Aurora Saint Lukes Medical Center - PILOT

Milwaukee, Wisconsin, 53215, United States

Location

Monash Health - PILOT

Clayton, Victoria, 3168, Australia

Location

The Alfred Hospital - PILOT

Melbourne, Australia

Location

Royal Prince Alfred Hospital - PILOT

Sydney, Australia

Location

Rigshospitalet - PILOT

Copenhagen, Denmark

Location

Helsinki University Hospital - PILOT

Helsinki, FL-00029 HUS, Finland

Location

Centre Hospitalier Régional Universitaire de Lille - PILOT

Lille, France

Location

Clinique Pasteur - PILOT

Toulouse, France

Location

Hygeia Hospital - PILOT

Athens, Greece

Location

Royal Sussex County Hospital - PILOT

Brighton, United Kingdom

Location

The Leeds Teaching Hospitals NHS Trust - Leeds General Infirmary - PILOT

Leeds, LS1 3EX, United Kingdom

Location

Guys & St Thomas NHS Foundation Trust - St Thomas Hospital - PILOT

London, United Kingdom

Location

Related Publications (3)

  • Tang GHL, Rajagopal V, Sorajja P, Bajwa T, Gooley R, Walton A, Modine T, Ng MK, Williams MR, Zajarias A, Hildick-Smith D, Tchetche D, Spargias K, Rajani R, Bapat VN, De Backer O, Blackman D, McCarthy P, Laine M, Jain R, Martin R, Thaden JJ, Marka NA, Mack M, Adams DH, Leon MB, Reardon MJ. Five-year outcomes of the early-generation Intrepid transapical transcatheter mitral valve replacement system. EuroIntervention. 2026 Feb 2;22(3):e172-e182. doi: 10.4244/EIJ-D-25-01133.

  • Zahr F, Song HK, Chadderdon SM, Gada H, Mumtaz M, Byrne T, Kirshner M, Bajwa T, Weiss E, Kodali S, George I, Heiser J, Merhi WM, Thaden JJ, Zhang A, Lim DS, Reardon MJ, Adams DH, Mack MJ, Leon MB. 30-Day Outcomes Following Transfemoral Transseptal Transcatheter Mitral Valve Replacement: Intrepid TMVR Early Feasibility Study Results. JACC Cardiovasc Interv. 2022 Jan 10;15(1):80-89. doi: 10.1016/j.jcin.2021.10.018. Epub 2021 Nov 6.

  • Bapat V, Rajagopal V, Meduri C, Farivar RS, Walton A, Duffy SJ, Gooley R, Almeida A, Reardon MJ, Kleiman NS, Spargias K, Pattakos S, Ng MK, Wilson M, Adams DH, Leon M, Mack MJ, Chenoweth S, Sorajja P; Intrepid Global Pilot Study Investigators. Early Experience With New Transcatheter Mitral Valve Replacement. J Am Coll Cardiol. 2018 Jan 2;71(1):12-21. doi: 10.1016/j.jacc.2017.10.061. Epub 2017 Nov 16.

MeSH Terms

Conditions

Mitral Valve Insufficiency

Condition Hierarchy (Ancestors)

Heart Valve DiseasesHeart DiseasesCardiovascular Diseases

Limitations and Caveats

NCT02322840 covers the PILOT study and the Early Feasibility Study (EFS)

Results Point of Contact

Title
Yetunde Ishola (Clinical Study Manager)
Organization
Medtronic

Study Officials

  • Lynnett Stahl

    Medtronic

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 31, 2014

First Posted

December 23, 2014

Study Start

April 1, 2015

Primary Completion

September 1, 2022

Study Completion (Estimated)

December 1, 2028

Last Updated

January 14, 2026

Results First Posted

November 24, 2025

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will not share

Locations